Galena Biopharma Launches Galena Patient Services (GPS)

PORTLAND, Ore., March 3, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the launch of Galena Patient Services (GPS), a full-service support program designed to enhance patient access to commercial products offered by the Company. Currently, Galena markets Abstral® (fentanyl) Sublingual Tablets for the treatment of breakthrough cancer pain. 

A dedicated GPS team works with the healthcare professionals, patients, and insurance providers to guide the benefits approval process and make prescribing and receiving Galena Biopharma commercial products as simple as possible. Enrollment in the GPS program is done quickly and easily through a patient's certified prescriber. An overview of the program can be found at

Galena Patient Services will:
  • Guide the benefits investigation and prior authorization process
  • Help manage the appeals and denials process
  • Locate the preferred pharmacy
  • Execute the Patient Assistance Program (PAP) for patient reimbursement support

"Patients suffering from breakthrough cancer pain are confronted with extraordinary issues on a daily basis, including insurance reimbursement and access," said Mark J. Ahn, Ph.D., President and Chief Executive Officer. "Galena Patient Services will offer support to these patients and their healthcare providers by managing the benefits approval process to make prescribing and receiving Abstral as simple as possible."  

All GPS services will be coordinated by a contracted third party vendor. All personal data in the GPS program are kept confidential to maintain HIPAA (Health Insurance Portability and Accountability Act) privacy standards.

About Abstral® (fentanyl) Sublingual Tablets

Abstral® (fentanyl) Sublingual Tablets are an important treatment option for inadequately controlled breakthrough cancer pain which impacts 40%-80% of cancer patients. Abstral is approved by the U.S. Food and Drug Administration, and is a sublingual (under the tongue) fentanyl tablet indicated only for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The innovative Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a more convenient sublingual tablet which rapidly dissolves under the tongue in seconds, provides rapid relief of breakthrough pain in minutes, and matches the duration of the entire pain episode. See full prescribing information at

Important Safety Information

ABSTRAL is an opioid agonist indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. 

If you liked this article you might like

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

How to Dig Deep for Value in These Exuberant Markets

Value Investors Have to Go Deeper

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments